MARKET

LIXTW

LIXTW

LIXTE BIOTECHNLG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5400
-0.0412
-7.09%
Closed 16:00 07/28 EDT
OPEN
0.5102
PREV CLOSE
0.5400
HIGH
0.5400
LOW
0.5000
VOLUME
101
TURNOVER
--
52 WEEK HIGH
6.77
52 WEEK LOW
0.2600
MARKET CAP
--
P/E (TTM)
-2.1693
1D
5D
1M
3M
1Y
5Y
LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer treatments, commented on pre-clinical research demonstr...
GlobeNewswire · 6d ago
Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer
Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine’s Cancer Biology program...
GlobeNewswire · 07/13 13:25
Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021
Presentation to highlight Company’s current clinical study of lead compound LB-100 for Small Cell Lung Cancer ALTADENA, CA, July 07, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte” or the “Company”), a clinical-stage dru...
GlobeNewswire · 07/07 13:35
WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc.
WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of a joint underwritten public offering of 1,200,000 shares for Lixte Biotechnology Holdings, Inc. (NASDAQ: Common stock – LIXT; Warra...
PR Newswire · 12/01/2020 20:28
WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)
WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the closing of the follow-on offering for its client Lixte Biotechnology Holdings, Inc. 1,200,000 units consisting of one share of common stock and one warrant were sold for a total of $5,700,000 in gross proceeds. Lixte Biotechnology Holdings, Inc. began trading on The Nasdaq Capital Market ("Nasdaq") on Wednesday, November 25, 2020 under the trading symbols "LIXT" and "LIXTW".
Business Wire · 11/30/2020 20:52
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LIXTW. Analyze the recent business situations of LIXTE BIOTECHNLG through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
  • All
  • Financials
  • Insiders
More
About LIXTW
Lixte Biotechnology Holdings, Inc. is a drug discovery company. The Company uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. It's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and includes two categories of compounds at various stages of pre-clinical and clinical development. It is developing two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of novel structures, which may be useful in the treatment of not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds which may be useful for the treatment of chronic hereditary diseases, such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases.

Webull offers kinds of Lixte Biotechnology Holdings Inc stock information, including NASDAQ:LIXTW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIXTW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LIXTW stock methods without spending real money on the virtual paper trading platform.